Trump probably indeed is “fatigued” as his doctor put it. You lose sleep as President, regardless the side you’re on. Illness in and of itself is reason to rest. He may very well have been feeling to effects of COVID while on the debate stage. Since COVID is a new illness and doctors will have differing opinions on treatment, his therapy is understandably a mixture or a cocktail.
Trump’s drug cocktail
Is the experimental antibody treatment by Regeneron. He was given an 8 gram dose. Trump is also taking vitamin D, zinc, famotidine, melatonin and daily aspirin.
The zinc alone will be a big help and the melatonin will help with rest. Sleep is a magic pill for healing for just about anything.
The cocktail is one of many experimental options
The most promising experimental treatment options may go onto being used nationwide. It’s only been tried on 275 patients recently but it shows promise. Trump is utilizing this under a “compassionate use request”.
Regeneron put out a statement: “In the USA, this type of compassionate use program is also known as an Expanded Access Program (EAP) and is intended for patients with serious or life-threatening conditions, who do not have any viable or available treatment options, and are unable to participate in ongoing clinical trials.”
The science behind the cocktail
George Yancopoulos, M.D., is the President and Chief Scientific Officer or Regeneron. “After months of incredibly hard work by our talented team, we are extremely gratified to see that Regeneron’s antibody cocktail REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response. These patients were less likely to clear the virus on their own, and were at greater risk for prolonged symptoms.”
Regeneron’s statement expounded on the two monoclonal antibodies. “The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science. Preclinical studies have shown that REGN-COV2 reduced the amount of virus and associated damage in the lungs of non-human primates.”